Anzeige
Meldung des Tages: Bohrtreffer, Infrastruktur, Finanzierung: Beginnt hier der Weg zur Produktion?

Amgen News

Aktie
WKN:  867900 ISIN:  US0311621009 US-Symbol:  AMGN Branche:  Pharmazeutika Land:  USA
296,80 €
+1,75 €
+0,59%
21:46:08 Uhr
Depot/Watchlist
Marktkapitalisierung *
152,02 Mrd. €
Streubesitz
15,92%
KGV
15,52
Dividende
8,52 EUR
Dividendenrendite
3,08%
Nachhaltigkeits-Score
46 %
Index-Zuordnung
Dow Jones Industrial Average
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,16: VH4VXJ
Werbung

Amgen News

11.12.25 - PR Newswire
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS
FDA APPROVES UPLIZNA® FOR ADULTS WITH GENERALIZED MYASTHENIA GRAVIS PR Newswire
09.12.25 - PR Newswire
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND
AMGEN ANNOUNCES 2026 FIRST QUARTER DIVIDEND PR Newswire
28.11.25 wallstreetONLINE Redaktion
Wer macht das Rennen?: Milliarden-Jackpot Adipositas: Amgen & Roche sagen Novo & Lilly den Kampf an!
Novo Nordisk und Eli Lilly waren Vorreiter bei Abnehmmitteln. Beiden wurde eine große Zukunft vorhergesagt. Doch die Konkurrenz ist größer geworden und nur Lilly konnte liefern. ...
24.11.25 - PR Newswire
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT CITI'S 2025 GLOBAL HEALTHCARE CONFERENCE PR Newswire
24.11.25 - PR Newswire
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE
AMGEN TO PRESENT AT THE 8TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE PR Newswire
12.11.25 - Landesbank Baden-Württemberg
Das KI-Karussell dreht sich weiter
Pharmawerte an der Börse gesucht Gestern profitierten die Börsen weiterhin von dem absehbaren Ende des US-​Regierungsstillstands. Der Euro Stoxx 50 legte 1,1 % auf 5.726 ...
08.11.25 - PR Newswire
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL
AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-​CV TRIAL PR Newswire
04.11.25 - PR Newswire
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS
AMGEN REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS PR Newswire
31.10.25 - PR Newswire
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND
AMGEN ANNOUNCES 2025 FOURTH QUARTER DIVIDEND PR Newswire
31.10.25 - PR Newswire
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025
AMGEN'S LANDMARK PHASE 3 REPATHA DATA TO BE PRESENTED AS LATE BREAKER AT THE AMERICAN HEART ASSOCIATION SCIENTIFIC SESSIONS 2025 PR Newswire
29.10.25 - PR Newswire
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS
AMGEN ANNOUNCES WEBCAST OF 2025 THIRD QUARTER FINANCIAL RESULTS PR Newswire
17.10.25 - PR Newswire
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
FDA APPROVES TEZSPIRE® FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPS PR Newswire
13.10.25 wallstreetONLINE Redaktion
Angst vor Verlusten?: Diese Aktie bringt Sie sicher und dividendenstark durch die nächste Korrektur!
Die Volatilität am Aktienmarkt ist "dank" US-​Präsident Donald Trump zurück. Die Aktie von US-​Pharmakonzern Pfizer bietet Sicherheit und stabile Cashflows. Willkommen zum ...
06.10.25 - PR Newswire
/C O R R E C T I O N -- Amgen/
/C O R R E C T I O N -- Amgen/ PR Newswire
02.10.25 - PR Newswire
LANDMARK PHASE 3 TRIAL (VESALIUS-CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS
LANDMARK PHASE 3 TRIAL (VESALIUS-​CV) MEETS PRIMARY ENDPOINTS IN A CARDIOVASCULAR PRIMARY PREVENTION STUDY OF 12,000 PATIENTS PR Newswire
26.09.25 - PR Newswire
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS
AMGEN ANNOUNCES $650M EXPANSION OF U.S. MANUFACTURING, CREATING HUNDREDS OF NEW JOBS PR Newswire
08.09.25 - PR Newswire
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
AMGEN AND KYOWA KIRIN ANNOUNCE TOP-LINE RESULTS FROM ROCATINLIMAB PHASE 3 ASCEND LONG-TERM EXTENSION STUDY IN ADULTS WITH MODERATE TO ...
04.09.25 - PR Newswire
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE PR Newswire
02.09.25 - PR Newswire
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-​OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS PR ...
29.08.25 - PR Newswire
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE PR Newswire

Newssuche

Videos

newspaper
09:50 Uhr +0,05%
Technical Trading: Treffsichere Signale für Gold
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »